Article preview reprinted Medtech Insight - September 2008
Find out how directed energy device-based medical therapies have greatly influenced the way physicians deliver care in a number of medical specialties.
Article preview reprinted Medtech Insight - September 2008
BPH: An Expanding Opportunity
The convergence of innovative technologies capable of harnessing a variety of powerful energy sources along with patients and physicians actively seeking more effective and less-invasive disease treatment options has created fertile opportunities in the field of directed energy (DE) device-based medical therapies. Devices that utilize laser, microwave, ultrasound, and radiofrequency (RF) energy have greatly influenced the way physicians deliver care in a number of medical specialties. One of the most dramatic areas of change has been in the management of benign prostatic hyperplasia (BPH), commonly referred to as an enlarged prostate. DE treatments in this area have become so popular there has been a noticeable decline in once standard surgical therapies since the late 1990s as patients have migrated to these less-invasive alternatives.
Expansion of Minimally Invasive, Energy-Based Therapies
The American Urological Association identifies electrosurgical transurethral resection of the prostate (TURP) as the gold standard for treating patients with BPH accompanied with severe symptoms or serious complications. However, electrosurgery is a highly invasive procedure that can cause additional complications, and more and more physicians are leaving this option as a last resort. As a result, the relative share of BPH patients undergoing electrosurgical treatment in the US is expected to decrease from about 4.0% of the actively treated population in 2007, to approximately 3.1% in 2011. Conversely, the use of DE therapies is expected to continue to experience solid growth during this period, with the penetration of laser-, microwave-, and RF-based therapies increasing from to 6.9% to 7.5% of the total actively treated BPH population by 2011.
Purchase this 3962-word article online as a PDF for just $125 and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.
Companies mentioned in this article:
American Medical Systems Holdings Inc.
Laserscope Inc.
Boston Scientific Corp.
Celsion Corp.
Iridex Corp.
Johnson & Johnson
Ethicon Inc.
Lumenis Ltd.
Medtronic Inc.
VidaMed Inc.
Olympus Corp.
Gyrus Group PLC
Gyrus ACMI
Trimedyne Inc.
Urologix Inc.
Medtech Insight delivers the quality content you need on medical technologies impacting the spectrum of surgical, orthopedic, cardiovascular, and other markets. Written and edited by seasoned industry participants and experts, the Medtech Insight newsletter provides insights into the technology and market developments (devices, instrumentation, biomaterials, gene therapy, tissue engineering, etc.) impacting a wide range of surgical and non-surgical clinical practices (cardiothoracic & vascular surgery, general surgery, orthopedics & spine surgery, interventional radiology/cardiology, etc.). Learn more at www.medtechinsight.com.
